IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 349-357

  Kothari, Poonam ^a   Pestana, Roberto ^a   Mesraoua, Rim ^a   Elchaki, Rim ^a   Faisal Khan, K M ^a   Dannenberg, Andrew J ^a   Falcone, Domenick J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; STAT3 PROTEIN;

ANIMAL CELL; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84891126479     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301906     Document Type: Article

References (63)

1. Mihara, M., M. Hashizume, H. Yoshida, M. Suzuki, and M. Shiina. 2012. IL-6/ IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. 122: 143-159.
2. Rincon, M. 2012. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 33: 571-577.
3. Lippitz, B. E. 2013. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14: e218-e228.
4. Schoels, M. M., D. van der Heijde, F. C. Breedveld, G. R. Burmester, M. Dougados, P. Emery, G. Ferraccioli, C. Gabay, A. Gibofsky, J. J. Gomez-Reino, et al. 2013. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. [Published erratum appears in 2013 Ann. Rheum. Dis. 72: 1110.] Ann. Rheum. Dis. 72: 583-589.
5. Danesh, J., S. Kaptoge, A. G. Mann, N. Sarwar, A. Wood, S. B. Angleman, F. Wensley, J. P. Higgins, L. Lennon, G. Eiriksdottir, et al. 2008. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 5: e78.
6. Eder, K., N. Baffy, A. Falus, and A. K. Fulop. 2009. The major inflammatory mediator interleukin-6 and obesity. Inflamm. Res. 58: 727-736.
7. Jones, S. A., J. Scheller, and S. Rose-John. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121: 3375-3383.
8. Waetzig, G. H., and S. Rose-John. 2012. Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin. Ther. Targets 16: 225-236.
9. Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Müller-Newen, and F. Schaper. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374: 1-20.
10. Eulenfeld, R., A. Dittrich, C. Khouri, P. J. Müller, B. Mütze, A. Wolf, and F. Schaper. 2012. Interleukin-6 signalling: more than Jaks and STATs. Eur. J. Cell Biol. 91: 486-495.
11. Itoh, T., H. Matsuda, M. Tanioka, K. Kuwabara, S. Itohara, and R. Suzuki. 2002. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169: 2643-2647.
12. Fernández, F. G., L. G. Campbell, W. Liu, J. M. Shipley, S. Itohara, G. A. Patterson, R. M. Senior, T. Mohanakumar, and A. Jaramillo. 2005. Inhibition of obliterative airway disease development in murine tracheal allografts by matrix metalloproteinase-9 deficiency. Am. J. Transplant. 5: 671-683.
13. Chantrain, C. F., H. Shimada, S. Jodele, S. Groshen, W. Ye, D. R. Shalinsky, Z. Werb, L. M. Coussens, and Y. A. DeClerck. 2004. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 64: 1675-1686.
14. Masson, V., L. R. de la Ballina, C. Munaut, B. Wielockx, M. Jost, C. Maillard, S. Blacher, K. Bajou, T. Itoh, S. Itohara, et al. 2005. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 19: 234-236.
15. Lessner, S. M., D. E. Martinson, and Z. S. Galis. 2004. Compensatory vascular remodeling during atherosclerotic lesion growth depends on matrix metalloproteinase-9 activity. Arterioscler. Thromb. Vasc. Biol. 24: 2123-2129.
16. Choi, E. T., E. T. Collins, L. A. Marine, M. G. Uberti, H. Uchida, J. E. Leidenfrost, M. F. Khan, K. P. Boc, D. R. Abendschein, and W. C. Parks. 2005. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25: 1020-1025.
17. Ikonomidis, J. S., J. R. Barbour, Z. Amani, R. E. Stroud, A. R. Herron, D. M. McClister, Jr., S. E. Camens, M. L. Lindsey, R. Mukherjee, and F. G. Spinale. 2005. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 112(9 Suppl.): I242-I248.
18. Opdenakker, G., P. E. Van den Steen, and J. Van Damme. 2001. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22: 571-579.
19. Parks, W. C., C. L. Wilson, and Y. S. López-Boado. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4: 617-629.
20. Kessenbrock, K., V. Plaks, and Z. Werb. 2010. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
21. Wahl, L. M., C. E. Olsen, A. L. Sandberg, and S. E. Mergenhagen. 1977. Prostaglandin regulation of macrophage collagenase production. Proc. Natl. Acad. Sci. USA 74: 4955-4958.
22. Shapiro, S. D., D. K. Kobayashi, A. P. Pentland, and H. G. Welgus. 1993. Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. J. Biol. Chem. 268: 8170-8175.
23. Corcoran, M. L., M. C. Kibbey, H. K. Kleinman, and L. M. Wahl. 1995. Laminin SIKVAV peptide induction of monocyte/macrophage prostaglandin E2 and matrix metalloproteinases. J. Biol. Chem. 270: 10365-10368.
24. Shankavaram, U. T., D. L. DeWitt, S. E. Funk, E. H. Sage, and L. M. Wahl. 1997. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell. Physiol. 173: 327-334.
25. Ottino, P., and H. E. P. Bazan. 2001. Corneal stimulation of MMP-1, -9 and uPA by platelet-activating factor is mediated by cyclooxygenase-2 metabolites. Curr. Eye Res. 23: 77-85.
26. Khan, K. M. F., L. R. Howe, and D. J. Falcone. 2004. Extracellular matrixinduced cyclooxygenase-2 regulates macrophage proteinase expression. J. Biol. Chem. 279: 22039-22046.
27. Pavlovic, S., B. Du, K. Sakamoto, K. M. F. Khan, C. Natarajan, R. M. Breyer, A. J. Dannenberg, and D. J. Falcone. 2006. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J. Biol. Chem. 281: 3321-3328.
28. Steenport, M., K. M. Khan, B. Du, S. E. Barnhard, A. J. Dannenberg, and D. J. Falcone. 2009. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J. Immunol. 183: 8119-8127.
29. Khan, K. M., P. Kothari, B. Du, A. J. Dannenberg, and D. J. Falcone. 2012. Matrix metalloproteinase-dependent microsomal prostaglandin E synthase-1 expression in macrophages: role of TNF- A and the EP4 prostanoid receptor. J. Immunol. 188: 1970-1980.
30. Uematsu, S., M. Matsumoto, K. Takeda, and S. Akira. 2002. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathionedependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/ MyD88/NF-IL6 pathway. J. Immunol. 168: 5811-5816.
31. Bezugla, Y., A. Kolada, S. Kamionka, B. Bernard, R. Scheibe, and P. Dieter. 2006. COX-1 and COX-2 contribute differentially to the LPS-induced release of PGE2 and TxA2 in liver macrophages. Prostaglandins Other Lipid Mediat. 79: 93-100.
32. Trebino, C. E., J. L. Stock, C. P. Gibbons, B. M. Naiman, T. S. Wachtmann, J. P. Umland, K. Pandher, J. M. Lapointe, S. Saha, M. L. Roach, et al. 2003. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. USA 100: 9044-9049.
33. Westman, M., M. Korotkova, E. af Klint, A. Stark, L. P. Audoly, L. Klareskog, A. K. Ulfgren, and P. J. Jakobsson. 2004. Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum. 50: 1774-1780.
34. Subbaramaiah, K., K. Yoshimatsu, E. Scherl, K. M. Das, K. D. Glazier, D. Golijanin, R. A. Soslow, T. Tanabe, H. Naraba, and A. J. Dannenberg. 2004. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J. Biol. Chem. 279: 12647-12658.
35. Otani, T., K. Yamaguchi, E. Scherl, B. Du, H. H. Tai, M. Greifer, L. Petrovic, T. Daikoku, S. K. Dey, K. Subbaramaiah, and A. J. Dannenberg. 2006. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G361-G368.
36. Tai, H. H., H. Cho, M. Tong, and Y. Ding. 2006. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des. 12: 955-962.
37. Edelson, P. J., and Z. A. Cohn. 1976. Purification and cultivation of monocytes and macrophages. In In Vitro Methods in Cell Mediated Tumor Immunity. B. R. Bloom, and J. R. David, eds. Academic Press, New York, p. 333-340.
38. Falcone, D. J., and M. J. Ferenc. 1988. Acetyl-LDL stimulates macrophagedependent plasminogen activation and degradation of extracellular matrix. J. Cell. Physiol. 135: 387-396.
39. Raschke, W. C., S. Baird, P. Ralph, and I. Nakoinz. 1978. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 15: 261-267.
40. Zar, J. H. 1984. Biostatistical Analysis, 2nd Ed. Prentice Hall, Englewood Cliffs, NJ.
41. Ikeda-Matsuo, Y., Y. Ikegaya, N. Matsuki, S. Uematsu, S. Akira, and Y. Sasaki. 2005. Microglia-specific expression of microsomal prostaglandin E2 synthase-1 contributes to lipopolysaccharide-induced prostaglandin E2 production. J. Neurochem. 94: 1546-1558.
42. Grötzinger, J., G. Kurapkat, A. Wollmer, M. Kalai, and S. Rose-John. 1997. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins 27: 96-109.
43. Legendre, F., J. Dudhia, J. P. Pujol, and P. Bogdanowicz. 2003. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R downregulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J. Biol. Chem. 278: 2903-2912.
44. Wang, X. Q., Y. P. Peng, J. H. Lu, B. B. Cao, and Y. H. Qiu. 2009. Neuroprotection of interleukin-6 against NMDA attack and its signal transduction by JAK and MAPK. Neurosci. Lett. 450: 122-126.
45. Saito, K., J. Iwashita, J. Murata, and T. Abe. 2006. The tyrosine kinase inhibitor AG490 inhibits growth of cancer cells and activates ERK in LS174T and HT-29 cells. Anticancer Res. 26(2A): 1085-1090.
46. Pattison, M. J., K. F. Mackenzie, and J. S. Arthur. 2012. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J. Immunol. 189: 2784-2792.
47. Reiterer, G., and A. Yen. 2006. Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication. Cancer Res. 66: 9083-9089.
48. Brasier, A. R. 2010. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc. Res. 86: 211-218.
49. Yang, J., X. Liao, M. K. Agarwal, L. Barnes, P. E. Auron, and G. R. Stark. 2007. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 21: 1396-1408.
50. Lacraz, S., L. P. Nicod, R. Chicheportiche, H. G. Welgus, and J. M. Dayer. 1995. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 96: 2304-2310.
51. Krishnamurthy, P., J. Rajasingh, E. Lambers, G. Qin, D. W. Losordo, and R. Kishore. 2009. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ. Res. 104: e9-e18.
52. Mostafa Mtairag, E., S. Chollet-Martin, M. Oudghiri, N. Laquay, M. P. Jacob, J. B. Michel, and L. J. Feldman. 2001. Effects of interleukin-10 on monocyte/ endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc. Res. 49: 882-890.
53. Caligiuri, G., M. Rudling, V. Ollivier, M. P. Jacob, J. B. Michel, G. K. Hansson, and A. Nicoletti. 2003. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med. 9: 10-17.
54. Matsumoto, H., H. Naraba, M. Murakami, I. Kudo, K. Yamaki, A. Ueno, and S. Oh-ishi. 1997. Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem. Biophys. Res. Commun. 230: 110-114.
55. Yoshimatsu, K., D. Golijanin, P. B. Paty, R. A. Soslow, P. J. Jakobsson, R. A. DeLellis, K. Subbaramaiah, and A. J. Dannenberg. 2001. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7: 3971-3976.
56. Yoshimatsu, K., N. K. Altorki, D. Golijanin, F. Zhang, P. J. Jakobsson, A. J. Dannenberg, and K. Subbaramaiah. 2001. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 7: 2669-2674.
57. Golijanin, D., J. Y. Tan, A. Kazior, E. G. Cohen, P. Russo, G. Dalbagni, K. J. Auborn, K. Subbaramaiah, and A. J. Dannenberg. 2004. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin. Cancer Res. 10: 1024-1031.
58. Boulet, L., M. Ouellet, K. P. Bateman, D. Ethier, M. D. Percival, D. Riendeau, J. A. Mancini, and N. Méthot. 2004. Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J. Biol. Chem. 279: 23229-23237.
59. Inada, M., C. Matsumoto, S. Uematsu, S. Akira, and C. Miyaura. 2006. Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation. J. Immunol. 177: 1879-1885.
60. Guschin, D., N. Rogers, J. Briscoe, B. Witthuhn, D. Watling, F. Horn, S. Pellegrini, K. Yasukawa, P. Heinrich, G. R. Stark, et al. 1995. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 14: 1421-1429.
61. Schaper, F., C. Gendo, M. Eck, J. Schmitz, C. Grimm, D. Anhuf, I. M. Kerr, and P. C. Heinrich. 1998. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem. J. 335: 557-565.
62. Schaeffer, M., M. Schneiderbauer, S. Weidler, R. Tavares, M. Warmuth, G. de Vos, and M. Hallek. 2001. Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Mol. Cell. Biol. 21: 8068-8081.
63. Iyer, S. S., and G. Cheng. 2012. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev. Immunol. 32: 23-63.